![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Gliomas are characterized by their invasiveness, angiogenesis, glycolysis and poor prognosis. Determining how to inhibit angiogenesis and glycolysis and induce cell death in gliomas is essential to the development of an effective therapy. CD147, a highly glycosylated transmembrane glycoprotein with two Ig-like extracellular domains that belongs to the immunoglobulin superfamily, plays an important role in the regulation of tumor invasiveness, angiogenesis and glycolysis by inducing the secretion of matrix metalloproteinases and vascular endothelial growth factor and by interacting with monocarboxylate transporters. In this review, we first summarize the roles played by CD147 in gliomas and then propose that CD147 may be a complementary prognostic biomarker and a possible therapeutic target for glioma treatment.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Malignant gliomas are incurable, even with advances in surgical techniques, chemoradiotherapy, targeted therapy and immunotherapy.
Developing effective treatments that address invasion, growth and angiogenesis in gliomas is essential for the development of a curative therapy.
CD147 is highly expressed in many malignant cancers. CD147 expression in tumor tissues is significantly higher than in normal tissues and is correlated with the degree of malignancy, metastasis and prognosis.
Expression of CD147 is associated with prognosis in glioma patients, suggesting a potential role for CD47 in glioma progression and management.
CD147 that is secreted by glioma cells can signal neighboring tumor cells to release matrix metalloproteinases, which degrade substrates and hydrolyze adhesive components on the tumor cell surface, leading to the promotion of cancer cell migration.
CD147 may be involved in angiogenesis in gliomas via matrix metalloproteinase-dependent and -independent mechanisms.
CD147 may be involved in glioma glycolysis by regulating lactate secretion through interference with MCTs.